Roth Capital affirms Regeneron (Nasdaq: REGN) at Buy with a $382 price target after the company and Sanofi reported new ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE